Shares of Orthofix International NV (NASDAQ:OFIX) reached a new 52-week high during trading on Monday . The company traded as high as $47.70 and last traded at $47.59, with a volume of 66,485 shares. The stock had previously closed at $46.70.

A number of research firms have recently commented on OFIX. Zacks Investment Research cut Orthofix International NV from a “buy” rating to a “hold” rating in a research report on Tuesday, July 5th. TheStreet upgraded Orthofix International NV from a “hold” rating to a “buy” rating in a research report on Monday, May 2nd.

The company has a market cap of $856.45 million and a PE ratio of 93.03. The stock’s 50-day moving average is $44.56 and its 200 day moving average is $41.51.

Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings results on Thursday, April 28th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.13. The company earned $98.70 million during the quarter, compared to analyst estimates of $93.10 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. On average, equities analysts expect that Orthofix International NV will post $1.35 earnings per share for the current fiscal year.

In other Orthofix International NV news, CEO Brad Mason sold 18,336 shares of the company’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $46.00, for a total value of $843,456.00. Following the completion of the transaction, the chief executive officer now directly owns 160,256 shares of the company’s stock, valued at approximately $7,371,776. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Michael Finegan sold 80,972 shares of the company’s stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $42.71, for a total transaction of $3,458,314.12. Following the completion of the transaction, the insider now directly owns 90,996 shares of the company’s stock, valued at $3,886,439.16. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its position in Orthofix International NV by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 34,774 shares of the medical device company’s stock worth $1,363,000 after buying an additional 600 shares during the last quarter. Marshall Wace LLP purchased a new position in Orthofix International NV during the fourth quarter worth $1,443,000. GSA Capital Partners LLP boosted its position in Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock worth $1,671,000 after buying an additional 6,601 shares during the last quarter. Russell Frank Co boosted its position in Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock worth $1,741,000 after buying an additional 19,582 shares during the last quarter. Finally, Teton Advisors Inc. boosted its position in Orthofix International NV by 7.1% in the fourth quarter. Teton Advisors Inc. now owns 45,200 shares of the medical device company’s stock worth $1,772,000 after buying an additional 3,000 shares during the last quarter.

Orthofix International N.V. (Orthofix) is a diversified, global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians across the world. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.